Abstract
Eribulin mesylate (Halaven®), a synthetic analogue of halichondrin B, is a welcome addition to the therapeutic options for treatment-refractory liposarcoma. It acts as a microtubule dynamics inhibitor, disrupting mitosis and leading to apoptotic cell death in cancer cells. Eribulin mesylate significantly improved overall and progression-free survival compared with dacarbazine and has a manageable tolerability profile in patients with unresectable, advanced liposarcoma whose disease has progressed following prior treatment, including an anthracycline-based regimen.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
